How would you treat cT3N1 ER/PR (-), Her2 (+) breast cancer who had mastectomy + ALND with a pCR in the nodes but ypT1 disease in the breast?  

The patient has tissue expanders in place and is receiving ado-trastuzumab emtansine.

Would you treat with PMRT? If so, would you target the CW and RNI, or treat CW only? Would you favor a hypo-fractionated or conventional course?



Answer from: Radiation Oncologist at Academic Institution

Answer from: Radiation Oncologist at Academic Institution

Answer from: Radiation Oncologist at Community Practice